Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid

Bonifáz, Alexandro; Tirado‐Sánchez, Andrés; Calderón, Luz; de, Griselda Montes; Torres‐Camacho, Paula; Ponce, Rosa María

doi:10.1080/09546634.2016.1178373

Cited by 15 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6 Amoxicillin/clavulanate can be used for cutaneous actinomycosis as suitable oral agents for a maximum of 12 weeks with considerable efficacy. 7…”

Section: Discussionmentioning

confidence: 99%

Scapular ulcero-nodular Actinomycosis masquerading as soft tissue tumour: A case report

Gupta,

Verma,

Ramchandani

2023

Trop Doct

View full text Add to dashboard Cite

“…5,6 Amoxicillin/clavulanate can be used for cutaneous actinomycosis as suitable oral agents for a maximum of 12 weeks with considerable efficacy. 7…”

Section: Discussionmentioning

confidence: 99%

Scapular ulcero-nodular Actinomycosis masquerading as soft tissue tumour: A case report

Gupta,

Verma,

Ramchandani

2023

Trop Doct

View full text Add to dashboard Cite

“…This short‐term administration may be less likely to cause the occurrence or development of severe cADR on the EM–SJS/TEN spectrum. In contrast, to treat chronic infectious and gastrointestinal diseases, constituent agents may be administrated for a longer period of time, and such longer‐term administration may be more likely to cause the occurrence or development of severe cADR. Second, antibiotics are usually prescribed for infectious conditions, and discrimination of whether the eruptions are caused by drug allergy or by infection itself is often difficult.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of cutaneous adverse drug reactions caused by triple‐combination drug therapy used for Helicobacter pylori eradication

Kikuchi

Nobeyama

Saeki

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Cutaneous adverse drug reactions (cADR) should be appropriately managed in drug administration. LANSAP®, Rabecure® and VONOSAP® are currently used for Helicobacter pylori eradication therapy. Here, we examined the characteristics of cADR caused by these drugs using data from the Pharmaceuticals and Medical Devices Agency (PMDA). Periods subject to analyses were set according to the year of release of these drugs: (i) from 2008 to 2017 for LANSAP; (ii) from 2014 to 2017 for Rabecure; and (iii) 2017 for VONOSAP. Among all cADR reported to the PMDA, those attributed to LANSAP, Rabecure and VONOSAP accounted for 2.3%, 1.0% and 3.6% of cases, respectively. cADR occurred in patients aged in their 20s or older, with the oldest patients aged in their 60s. Numbers of male and female patients were 28 and 70 for LANSAP, eight and 14 for Rabecure and three and 16 for VONOSAP, respectively. Statistical analyses revealed significant sex differences for LANSAP (P = 0.022) and VONOSAP (P = 0.012), but not for Rabecure (P = 0.729). LANSAP, Rabecure or VONOSAP caused erythema multiforme in the largest population of patients and Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in three patients. Ratios of SJS/TEN were 0.0–5.3% for LANSAP, Rabecure or VONOSAP, but 11.5–44.8% for the corresponding single constituent drugs other than vonoprazan. In conclusion, female sex appears to represent a risk factor for cADR attributed to H. pylori eradication therapy using LANSAP or VONOSAP, although H. pylori eradication therapy without these drugs rarely causes severe cADR.

show abstract

“…Actinomyces remain highly sensitive to Penicillin; however, if Penicillin allergy is present, tetracycline and macrolides are alternative options [1, 2]. In the case of cutaneous actinomycosis, oral amoxicillin and clavulanic acid have been used in place of IV Penicillin with success [16]. Surgery is reserved for infections with a necrotic nidus, large infectious burden, fistulas, and abscesses [1, 6, 7].…”

Section: Discussionmentioning

confidence: 99%

Esophageal Stricture Caused by Actinomyces in a Patient with No Apparent Predisposing Factors

Zhang

Guss

Mohanty

2019

Case Reports in Gastrointestinal Medicine

View full text Add to dashboard Cite

Actinomyces species are Gram positive anaerobic or microaerophilic bacteria that are part of the human flora in the oropharyngeal, gastrointestinal, and genitourinary tract. In the presence of a mucosal injury, they can become pathogenic and infect the underlying tissue without respect for tissue planes, leading to abscesses, fistulas, and sinus tracts. Through contiguous and hematogenous spread, virtually any organ can become infected. The presentation can be myriad and often mimics tumors, tuberculosis, or other more common infections and inflammatory conditions. While the cervicofacial region is the most common site of infection, involvement of the esophagus is unusual. Esophageal actinomycosis mostly occurs in patients with compromised immunity or prior esophageal injuries. Occurrence in immunocompetent individuals without risk factors is exceedingly rare. We report a case of esophageal actinomycosis complicated by an esophageal stricture in a patient with no apparent predisposing conditions.

show abstract

Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid

Abstract: Treatment with AMX/CLV acid showed efficacy in the management of actinomycosis with cutaneous involvement.

Cited by 15 publications

References 32 publications

Scapular ulcero-nodular Actinomycosis masquerading as soft tissue tumour: A case report

Scapular ulcero-nodular Actinomycosis masquerading as soft tissue tumour: A case report

Characteristics of cutaneous adverse drug reactions caused by triple‐combination drug therapy used for Helicobacter pylori eradication

Esophageal Stricture Caused by Actinomyces in a Patient with No Apparent Predisposing Factors

Contact Info

Product

Resources

About